Data gathered: July 1
AI Stock Analysis - Incyte (INCY)
Analysis generated June 17, 2024. Powered by Chat GPT.
Incyte Corporation (INCY) is a well-established biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The firm's portfolio includes products aimed at treating various cancer types, inflammatory diseases, and more. Incyte leverages its strong research and development capabilities to maintain a competitive edge in an evolving market.
Stock Alerts - Incyte (INCY)
 |
Incyte | June 27 News Alert: Incyte Stock Rises as Pharmaceutical Firm Appoints New CEO |
|
Incyte | June 17 Business Outlook among employees is up by 10.5% over the last month. |
|
Incyte | June 6 Insider Alert: Denton Sheila A. is selling shares |
|
Incyte | June 4 Insider Alert: Tray Thomas is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Incyte
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 111 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 48,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 36 | Sign up | Sign up | Sign up |
| Patents | 516 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 676 | Sign up | Sign up | Sign up |
| Facebook Followers | 4,853 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,406 | Sign up | Sign up | Sign up |
| Twitter Followers | 6,451 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| Youtube Subscribers | 270 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 63 | Sign up | Sign up | Sign up |
| Linkedin Employees | 3,176 | Sign up | Sign up | Sign up |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally.
| Price | $68.73 |
| Target Price | Sign up |
| Volume | 1,490,000 |
| Market Cap | $13.2B |
| Year Range | $55.17 - $83.38 |
| Dividend Yield | 0% |
| PE Ratio | 341.85 |
| Analyst Rating | 36% buy |
| Industry | Biotechnology |
In the news
 |
Notable Insider Move: William Meury Takes Part In Options Exercise At Incyte, Resulting In $0July 1 - Biztoc.com |
 |
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”June 30 - Yahoo Entertainment |
 |
Incyte Stock Gets Relative Strength Rating LiftJune 27 - Investor's Business Daily |
 |
Incyte Corporation (NASDAQ:INCY) Shares Purchased by Chevy Chase Trust Holdings LLCJune 27 - ETF Daily News |
|
Janney Montgomery Scott LLC Boosts Stock Position in Incyte Corporation (NASDAQ:INCY)June 27 - ETF Daily News |
 |
Incyte Stock Rises as Pharmaceutical Firm Appoints New CEOJune 26 - Investopedia |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 1.05B | 73M | 980M | 158M | 205M | 1.160 |
| Q4 '24 | 1.18B | 89M | 1.09B | 201M | 337M | 1.430 |
| Q3 '24 | 1.14B | 86M | 1.05B | 106M | 180M | 1.070 |
| Q2 '24 | 1.04B | 93M | 951M | -445M | -367M | -1.820 |
| Q1 '24 | 881M | 61M | 820M | 170M | 114M | 0.640 |
Insider Transactions View All
| Denton Sheila A. filed to sell 26,504 shares at $68. June 5 '25 |
| Tray Thomas filed to sell 22,003 shares at $64.9. June 3 '25 |
| Tray Thomas filed to sell 22,654 shares at $65.7. June 3 '25 |
| Flannelly Barry P filed to sell 52,714 shares at $67.9. March 18 '25 |
| Flannelly Barry P filed to sell 52,913 shares at $67.9. March 18 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Jun 2, 25 | Sell | $1K - $15K |
| Ro Khanna |
Oct 8, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
May 6, 24 | Sell | $1K - $15K |
Read more about Incyte (INCY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Incyte?
The Market Cap of Incyte is $13.2B.
What is Incyte's PE Ratio?
As of today, Incyte's PE (Price to Earnings) ratio is 341.85.
What is the current stock price of Incyte?
Currently, the price of one share of Incyte stock is $68.73.
How can I analyze the INCY stock price chart for investment decisions?
The INCY stock price chart above provides a comprehensive visual representation of Incyte's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Incyte shares. Our platform offers an up-to-date INCY stock price chart, along with technical data analysis and alternative data insights.
Does INCY offer dividends to its shareholders?
As of our latest update, Incyte (INCY) does not offer dividends to its shareholders. Investors interested in Incyte should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Incyte?
Some of the similar stocks of Incyte are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.